Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6
The cardiomyopathic Syrian hamster (CMH) of the strain BIO 14:6 is a model for both cardiac and skeletal muscle abnormalities. It has reduced longevity and noticeable hypertrophy of the heart and liver. At 220 days, CMHs display a total Ca 2+ overload, 1.3–1.8-fold normal and a cytosolic Ca 2+ conce...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 1997-06, Vol.328 (2), p.163-174 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 174 |
|---|---|
| container_issue | 2 |
| container_start_page | 163 |
| container_title | European journal of pharmacology |
| container_volume | 328 |
| creator | D'hahan, Nathalie Taouil, Karima Dassouli, Abdelilah Jean-Emile Morel |
| description | The cardiomyopathic Syrian hamster (CMH) of the strain BIO 14:6 is a model for both cardiac and skeletal muscle abnormalities. It has reduced longevity and noticeable hypertrophy of the heart and liver. At 220 days, CMHs display a total Ca
2+ overload, 1.3–1.8-fold normal and a cytosolic Ca
2+ concentration 2–4-fold higher than normal. Long-term oral treatment (18 mg/kg per day) with trimetazidine (anti-ischaemic drug), from age 30 to 350 days, was more efficient than the standard Ca
2+ blocker verapamil. Trimetazidine increased the median survival time of CMH by 57% and the hypertrophy disappeared. The total Ca
2+ level in CMHs reverted to that of normal Syrian hamsters (F1B). The cytosolic Ca
2+ overload was limited to a factor of ≅2. Therefore, trimetazidine possesses anti-Ca
2+ properties and is effective in increasing survival and decreasing the heart and liver hypertrophy of CMH. This suggests that trimetazidine may be valuable in the prevention of congestive heart failure of similar aetiology. |
| doi_str_mv | 10.1016/S0014-2999(97)83042-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79130936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299997830427</els_id><sourcerecordid>79130936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-cb6eb4707431abfba32ea3179ff2f10b4ad1ed6631bd7f4ff418439936c6cc4e3</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EgvL4BCQvEIJFwBO7ccwGAeIlVeoCWFuOM6ZGTVJsF1S-ntBW3bKaxZw7j0PIMbALYFBcvjAGIsuVUmdKnpeciTyTW2QApVQZk5Bvk8EG2SP7MX4wxoYqH-6SXZVDWahyQMajrn3PEoaGpgkGM1vQb58mNAXfYDI_vvYtUt9Sa0Ltu2bRzUyaeEtfFsGblk5ME_s0vX0eUxBXxSHZcWYa8WhdD8jbw_3r3VM2Gj8-392MMisEpMxWBVZCMik4mMpVhudoOEjlXO6AVcLUgHVRcKhq6YRzAkrBleKFLawVyA_I6WruLHSfc4xJNz5anE5Ni908aqmAsx7vweEKtKGLMaDTs_41ExYamP4TqZci9Z8lraReitSyzx2vF8yrButNam2u75-s-yZaM3XBtNbHDZZLXrIh77HrFYa9jC-PQUfrsbVY-4A26brz_xzyC3Moj3w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79130936</pqid></control><display><type>article</type><title>Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>D'hahan, Nathalie ; Taouil, Karima ; Dassouli, Abdelilah ; Jean-Emile Morel</creator><creatorcontrib>D'hahan, Nathalie ; Taouil, Karima ; Dassouli, Abdelilah ; Jean-Emile Morel</creatorcontrib><description>The cardiomyopathic Syrian hamster (CMH) of the strain BIO 14:6 is a model for both cardiac and skeletal muscle abnormalities. It has reduced longevity and noticeable hypertrophy of the heart and liver. At 220 days, CMHs display a total Ca
2+ overload, 1.3–1.8-fold normal and a cytosolic Ca
2+ concentration 2–4-fold higher than normal. Long-term oral treatment (18 mg/kg per day) with trimetazidine (anti-ischaemic drug), from age 30 to 350 days, was more efficient than the standard Ca
2+ blocker verapamil. Trimetazidine increased the median survival time of CMH by 57% and the hypertrophy disappeared. The total Ca
2+ level in CMHs reverted to that of normal Syrian hamsters (F1B). The cytosolic Ca
2+ overload was limited to a factor of ≅2. Therefore, trimetazidine possesses anti-Ca
2+ properties and is effective in increasing survival and decreasing the heart and liver hypertrophy of CMH. This suggests that trimetazidine may be valuable in the prevention of congestive heart failure of similar aetiology.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(97)83042-7</identifier><identifier>PMID: 9218698</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Animals ; Antianginal agents. Coronary vasodilator agents ; Biological and medical sciences ; Ca 2 ; Calcium - analysis ; Calcium Channel Blockers - blood ; Calcium Channel Blockers - therapeutic use ; Cardiomyopathy ; Cardiomyopathy, Hypertrophic - blood ; Cardiomyopathy, Hypertrophic - drug therapy ; Cardiomyopathy, Hypertrophic - pathology ; Cardiovascular system ; Cricetinae ; Heart Ventricles - chemistry ; Heart Ventricles - pathology ; Hypertrophy ; In Vitro Techniques ; Ischemia ; Long-Term Care ; Medical sciences ; Mesocricetus ; Myocardium - chemistry ; Myocardium - pathology ; Pharmacology. Drug treatments ; Survival Rate ; Trimetazidine ; Trimetazidine - blood ; Trimetazidine - therapeutic use ; Vasodilator Agents - blood ; Vasodilator Agents - therapeutic use ; Verapamil ; Verapamil - therapeutic use</subject><ispartof>European journal of pharmacology, 1997-06, Vol.328 (2), p.163-174</ispartof><rights>1997 Elsevier Science B.V.</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-cb6eb4707431abfba32ea3179ff2f10b4ad1ed6631bd7f4ff418439936c6cc4e3</citedby><cites>FETCH-LOGICAL-c441t-cb6eb4707431abfba32ea3179ff2f10b4ad1ed6631bd7f4ff418439936c6cc4e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0014-2999(97)83042-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2738053$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9218698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>D'hahan, Nathalie</creatorcontrib><creatorcontrib>Taouil, Karima</creatorcontrib><creatorcontrib>Dassouli, Abdelilah</creatorcontrib><creatorcontrib>Jean-Emile Morel</creatorcontrib><title>Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>The cardiomyopathic Syrian hamster (CMH) of the strain BIO 14:6 is a model for both cardiac and skeletal muscle abnormalities. It has reduced longevity and noticeable hypertrophy of the heart and liver. At 220 days, CMHs display a total Ca
2+ overload, 1.3–1.8-fold normal and a cytosolic Ca
2+ concentration 2–4-fold higher than normal. Long-term oral treatment (18 mg/kg per day) with trimetazidine (anti-ischaemic drug), from age 30 to 350 days, was more efficient than the standard Ca
2+ blocker verapamil. Trimetazidine increased the median survival time of CMH by 57% and the hypertrophy disappeared. The total Ca
2+ level in CMHs reverted to that of normal Syrian hamsters (F1B). The cytosolic Ca
2+ overload was limited to a factor of ≅2. Therefore, trimetazidine possesses anti-Ca
2+ properties and is effective in increasing survival and decreasing the heart and liver hypertrophy of CMH. This suggests that trimetazidine may be valuable in the prevention of congestive heart failure of similar aetiology.</description><subject>Animals</subject><subject>Antianginal agents. Coronary vasodilator agents</subject><subject>Biological and medical sciences</subject><subject>Ca 2</subject><subject>Calcium - analysis</subject><subject>Calcium Channel Blockers - blood</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cardiomyopathy</subject><subject>Cardiomyopathy, Hypertrophic - blood</subject><subject>Cardiomyopathy, Hypertrophic - drug therapy</subject><subject>Cardiomyopathy, Hypertrophic - pathology</subject><subject>Cardiovascular system</subject><subject>Cricetinae</subject><subject>Heart Ventricles - chemistry</subject><subject>Heart Ventricles - pathology</subject><subject>Hypertrophy</subject><subject>In Vitro Techniques</subject><subject>Ischemia</subject><subject>Long-Term Care</subject><subject>Medical sciences</subject><subject>Mesocricetus</subject><subject>Myocardium - chemistry</subject><subject>Myocardium - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Survival Rate</subject><subject>Trimetazidine</subject><subject>Trimetazidine - blood</subject><subject>Trimetazidine - therapeutic use</subject><subject>Vasodilator Agents - blood</subject><subject>Vasodilator Agents - therapeutic use</subject><subject>Verapamil</subject><subject>Verapamil - therapeutic use</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EgvL4BCQvEIJFwBO7ccwGAeIlVeoCWFuOM6ZGTVJsF1S-ntBW3bKaxZw7j0PIMbALYFBcvjAGIsuVUmdKnpeciTyTW2QApVQZk5Bvk8EG2SP7MX4wxoYqH-6SXZVDWahyQMajrn3PEoaGpgkGM1vQb58mNAXfYDI_vvYtUt9Sa0Ltu2bRzUyaeEtfFsGblk5ME_s0vX0eUxBXxSHZcWYa8WhdD8jbw_3r3VM2Gj8-392MMisEpMxWBVZCMik4mMpVhudoOEjlXO6AVcLUgHVRcKhq6YRzAkrBleKFLawVyA_I6WruLHSfc4xJNz5anE5Ni908aqmAsx7vweEKtKGLMaDTs_41ExYamP4TqZci9Z8lraReitSyzx2vF8yrButNam2u75-s-yZaM3XBtNbHDZZLXrIh77HrFYa9jC-PQUfrsbVY-4A26brz_xzyC3Moj3w</recordid><startdate>19970611</startdate><enddate>19970611</enddate><creator>D'hahan, Nathalie</creator><creator>Taouil, Karima</creator><creator>Dassouli, Abdelilah</creator><creator>Jean-Emile Morel</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970611</creationdate><title>Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6</title><author>D'hahan, Nathalie ; Taouil, Karima ; Dassouli, Abdelilah ; Jean-Emile Morel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-cb6eb4707431abfba32ea3179ff2f10b4ad1ed6631bd7f4ff418439936c6cc4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Antianginal agents. Coronary vasodilator agents</topic><topic>Biological and medical sciences</topic><topic>Ca 2</topic><topic>Calcium - analysis</topic><topic>Calcium Channel Blockers - blood</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cardiomyopathy</topic><topic>Cardiomyopathy, Hypertrophic - blood</topic><topic>Cardiomyopathy, Hypertrophic - drug therapy</topic><topic>Cardiomyopathy, Hypertrophic - pathology</topic><topic>Cardiovascular system</topic><topic>Cricetinae</topic><topic>Heart Ventricles - chemistry</topic><topic>Heart Ventricles - pathology</topic><topic>Hypertrophy</topic><topic>In Vitro Techniques</topic><topic>Ischemia</topic><topic>Long-Term Care</topic><topic>Medical sciences</topic><topic>Mesocricetus</topic><topic>Myocardium - chemistry</topic><topic>Myocardium - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Survival Rate</topic><topic>Trimetazidine</topic><topic>Trimetazidine - blood</topic><topic>Trimetazidine - therapeutic use</topic><topic>Vasodilator Agents - blood</topic><topic>Vasodilator Agents - therapeutic use</topic><topic>Verapamil</topic><topic>Verapamil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>D'hahan, Nathalie</creatorcontrib><creatorcontrib>Taouil, Karima</creatorcontrib><creatorcontrib>Dassouli, Abdelilah</creatorcontrib><creatorcontrib>Jean-Emile Morel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>D'hahan, Nathalie</au><au>Taouil, Karima</au><au>Dassouli, Abdelilah</au><au>Jean-Emile Morel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>1997-06-11</date><risdate>1997</risdate><volume>328</volume><issue>2</issue><spage>163</spage><epage>174</epage><pages>163-174</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>The cardiomyopathic Syrian hamster (CMH) of the strain BIO 14:6 is a model for both cardiac and skeletal muscle abnormalities. It has reduced longevity and noticeable hypertrophy of the heart and liver. At 220 days, CMHs display a total Ca
2+ overload, 1.3–1.8-fold normal and a cytosolic Ca
2+ concentration 2–4-fold higher than normal. Long-term oral treatment (18 mg/kg per day) with trimetazidine (anti-ischaemic drug), from age 30 to 350 days, was more efficient than the standard Ca
2+ blocker verapamil. Trimetazidine increased the median survival time of CMH by 57% and the hypertrophy disappeared. The total Ca
2+ level in CMHs reverted to that of normal Syrian hamsters (F1B). The cytosolic Ca
2+ overload was limited to a factor of ≅2. Therefore, trimetazidine possesses anti-Ca
2+ properties and is effective in increasing survival and decreasing the heart and liver hypertrophy of CMH. This suggests that trimetazidine may be valuable in the prevention of congestive heart failure of similar aetiology.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>9218698</pmid><doi>10.1016/S0014-2999(97)83042-7</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 1997-06, Vol.328 (2), p.163-174 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79130936 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Antianginal agents. Coronary vasodilator agents Biological and medical sciences Ca 2 Calcium - analysis Calcium Channel Blockers - blood Calcium Channel Blockers - therapeutic use Cardiomyopathy Cardiomyopathy, Hypertrophic - blood Cardiomyopathy, Hypertrophic - drug therapy Cardiomyopathy, Hypertrophic - pathology Cardiovascular system Cricetinae Heart Ventricles - chemistry Heart Ventricles - pathology Hypertrophy In Vitro Techniques Ischemia Long-Term Care Medical sciences Mesocricetus Myocardium - chemistry Myocardium - pathology Pharmacology. Drug treatments Survival Rate Trimetazidine Trimetazidine - blood Trimetazidine - therapeutic use Vasodilator Agents - blood Vasodilator Agents - therapeutic use Verapamil Verapamil - therapeutic use |
| title | Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T05%3A32%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20therapy%20with%20trimetazidine%20in%20cardiomyopathic%20Syrian%20hamster%20BIO%2014:6&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=D'hahan,%20Nathalie&rft.date=1997-06-11&rft.volume=328&rft.issue=2&rft.spage=163&rft.epage=174&rft.pages=163-174&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(97)83042-7&rft_dat=%3Cproquest_cross%3E79130936%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79130936&rft_id=info:pmid/9218698&rft_els_id=S0014299997830427&rfr_iscdi=true |